Literature DB >> 6379758

Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers.

E Ekblad, L Edvinsson, C Wahlestedt, R Uddman, R Håkanson, F Sundler.   

Abstract

Neuropeptide Y (NPY)-immunoreactive nerve fibers were numerous around arteries and few around veins. NPY probably co-exists with noradrenaline in such fibers since chemical or surgical sympathectomy eliminated both NPY and noradrenaline from perivascular nerve fibers and since double staining demonstrated dopamine-beta-hydroxylase, the enzyme that catalyzes the conversion of dopamine to noradrenaline, and NPY in the same perivascular nerve fibers. Studies on isolated blood vessels indicated that NPY is not a particularly potent contractile agent in vitro. NPY greatly enhanced the adrenergically mediate contractile response to electrical stimulation and to application of adrenaline, noradrenaline or histamine, as studied in the isolated rabbit gastro-epiploic and femoral arteries. The potentiating effect of NPY on the response to electrical stimulation is probably not presynaptic since NPY affected neither the spontaneous nor the electrically evoked release of [3H]noradrenaline from perivascular sympathetic nerve fibers.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6379758     DOI: 10.1016/0167-0115(84)90064-8

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  134 in total

1.  Effects of sympathetic activity and galanin on cardiac vagal action in anaesthetized cats.

Authors:  L G Ulman; E K Potter; D I McCloskey
Journal:  J Physiol       Date:  1992-03       Impact factor: 5.182

2.  Sympathetic-parasympathetic interactions at the heart, possibly involving neuropeptide Y, in anaesthetized dogs.

Authors:  M L Revington; D I McCloskey
Journal:  J Physiol       Date:  1990-09       Impact factor: 5.182

3.  Modulation of noradrenaline and neuropeptide Y (NPY) release in the pig kidney in vivo: involvement of alpha 2, NPY and angiotensin II receptors.

Authors:  J Pernow; J M Lundberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

4.  NPY/Y₁ receptor-mediated vasoconstrictory and proliferative effects in pulmonary hypertension.

Authors:  S Crnkovic; B Egemnazarov; P Jain; U Seay; N Gattinger; L M Marsh; Z Bálint; G Kovacs; B Ghanim; W Klepetko; R T Schermuly; N Weissmann; A Olschewski; G Kwapiszewska
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

5.  Vasoconstrictor effects of various neuropeptide Y analogues on the rat tail artery in the presence of phenylephrine.

Authors:  M Tschöpl; R C Miller; J Pelton; J C Stoclet; B Bucher
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

6.  The ability of neuropeptide Y to mediate responses in the murine cutaneous microvasculature: an analysis of the contribution of Y1 and Y2 receptors.

Authors:  Duc Quyen Chu; Helen M Cox; Soraia K P Costa; Herbert Herzog; Susan D Brain
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

7.  Evoked noradrenaline release in the rabbit ear artery: enhancement by purines, attenuation by neuropeptide Y and lack of effect of calcitonin gene-related peptide.

Authors:  K I Maynard; G Burnstock
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

8.  Development of peptide-containing nerves in the human fetal prostate gland.

Authors:  P Y Jen; J S Dixon
Journal:  J Anat       Date:  1995-08       Impact factor: 2.610

9.  Discrimination by benextramine between the NPY-Y1 receptor subtypes present in rabbit isolated vas deferens and saphenous vein.

Authors:  S Palea; M Corsi; J M Rimland; D G Trist
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

10.  Production, characterization, and expression of neuropeptide Y by human pheochromocytoma.

Authors:  P deS Senanayake; J Denker; E L Bravo; R M Graham
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.